Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $15.7352W HIGH $30.00
Volume
7.56 M
Value Traded
230.43 M
Short % Float
4.52%
+1.75%Week
-2.01%1 Month
+5.66%3 Month
+39.36%6 Month
-76.91%5 Year
+1,310%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
12.36 B
EPS (TTM)
-2.06
P/E Ratio
-
Ent. Value
10.21 B
Total Shares
517.00 M
Float Shares
513.70 M
Insiders
0.64%
Institutions
109.61%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BAX Catalyst Timeline
Dated clinical, regulatory and corporate events for Baxter International Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Baxter International Inc.
224Total events
2Upcoming
47Tier-1 (high impact)
2016 to 2026Coverage
Upcoming catalysts 2
Event history 50
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference presentation
◆Management ChangeCorporate
William Ampofo to become Quality and Regulatory Compliance Committee Chair
●Management ChangeCorporate
Cathy R. Smith and Stephen H. Rusckowski resign from Baxter board
◆Oral PresentationPresentation
Real-world data on Spectrum IQ LVP EMR integration presented at ASHP 2025 Midyear Clinical Meeting
◆Management ChangeCorporate
Separated CEO and Chair roles, Brent Shafer as Non-Executive Chair
▲Partnership / LicenseCorporate
Partnership with Vizient to include IV fluids in Vizient Reserve Program
▲Product LaunchPost-Market
Launched Hemopatch Sealing Hemostat with room temperature storage in Europe
◆Management ChangeCorporate
CEO Jos (Joe) E. Almeida retires effective immediately; Brent Shafer appointed Chair and Interim CEO
●Product LaunchProgressaPost-Market
Planned launch of Progressa+ in additional global markets
critical caresource ↗
●Oral PresentationPresentation
Real-world data on Spectrum IQ infusion pump integration presented at ASHP 2025 Midyear Clinical Meeting
◆Quarterly UpdateCorporate
2025 financial objectives: 4-5% operational sales growth, ~16.5% adjusted operating margin
▲Timing GuidancePresentation
Post-divestiture targets: operational sales growth 4-5% annually, FY2025 adjusted operating margin ~16.5%
▲Manufacturing MilestoneCMC / Inspection
Restarted highest-throughput IV solutions manufacturing line at North Cove facility
▲Timing GuidancePresentation
New product from North Cove expected to begin shipping by end of November
◆Quarterly UpdateCorporate
Third quarter 2024 earnings announcement to include Hurricane Helene impact update
▼Supply DisruptionCMC / Inspection
North Cove facility closed due to Hurricane Helene flooding
◆Quarterly UpdateCorporate
Baxter expects to post financial schedules reflecting Kidney Care as discontinued operation prior to Q3 2024 earnings
Past FDA Catalysts and PDUFA Decisions
How BAX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-08-14 | Sodium Bicarbonate | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D27 / 100
Pipeline Score
$60M
Pipeline Value
Not rated
Valuation Signal
2
Drugs Scored
-
rNPV / MCap
Top 76%
Mid Cap(rank 500 of 658)
Percentile Rank
Baxter International Inc. faces pipeline headwinds (27/100), with $70M risk-adjusted pipeline value, led by Numeta GE in Parenteral Nutrition (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Numeta GE Small moleculeCompletedNCT06842134 | Parenteral Nutrition | Phase 1 | COMPLETED | 16 | May 22, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every BAX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Wilkes David S.Director | Grant/Award | 12,836 37,076 held | $0.00 | 05/05/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BAX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 0.7 % (-61.1 %) | 7.57 M | 250.00 K | -50% ( -250.00 K) |
BAX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-09 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BAX ranks across every disease it competes in
Competitive Position is a premium feature
See how BAX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBAX News
BAX▼ -0.3%today
Baxter to Host Third-Quarter 2026 Financial Results Conference Call for Investors
Baxter International Inc. will host a conference call on October 29, 2026, to discuss its third-quarter financial results. The call is scheduled for 7:30 a.m. Central Time and will be accessible through pre-registration. Additionally, it will be webcasted on Baxter's official website, allowing broader investor engagement.
Read more →BAXBaxter Releases Inaugural Connected Hospital Report
Baxter International Inc. has released its inaugural 2026 Connected Hospital Report, which provides insights into how U.S. hospitals are utilizing technology to enhance clinical and operational performance. The report is based on a survey of 150 IT and nursing leaders, focusing on the progress hospitals are making in their 'connected hospital' journey.
Read more →BAXBaxter Appoints John Rogers Chief Financial Officer
Baxter International Inc. has appointed John Rogers as the new Chief Financial Officer, effective October 1, 2026. Rogers, who will report to CEO Andrew Hider, is recognized for his global finance experience and success in leading transformation initiatives. This appointment is expected to enhance Baxter's financial leadership.
Read more →BAXBaxter Announces Pricing for Its Upsized Cash Tender Offers
Baxter International Inc. has announced the pricing for its upsized cash tender offers for validly tendered notes. The offers will utilize a 'waterfall' methodology to prioritize acceptance based on specified levels. This move reflects the company's strategic financial management and aims to optimize its capital structure.
Read more →BAXBaxter Announces Early Tender Results and Upsizing of Previously Announced Cash Tender Offers
Baxter International Inc. has announced the early results of its cash tender offers for validly tendered notes. The company plans to upsize these offers, reflecting positive investor engagement. This move is part of Baxter's strategy to manage its debt effectively and optimize its capital structure.
Read more →BAXBaxter Announces Cash Tender Offers
Baxter International Inc. has initiated cash tender offers for its notes, with a maximum purchase price of $500 million. The company aims to buy back validly tendered notes to optimize its capital structure. This move is seen as a strategic effort to manage debt effectively and potentially increase shareholder value.
Read more →BAX▲ +8%on this newsshared move
Baxter Reports Second-Quarter 2026 Results
Baxter International Inc. reported strong second-quarter results for 2026, surpassing expectations on both revenue and profit. The company's performance was bolstered by solid operating results and an unanticipated tariff refund. CEO Andrew Hider expressed optimism about the company's ongoing progress and core operating momentum.
Read more →BAXBaxter to Host Second-Quarter 2026 Financial Results Conference Call for Investors
Baxter International Inc. will conduct a conference call on July 30, 2026, to discuss its second-quarter financial results. The call is scheduled for 7:30 a.m. Central Time and will be accessible via pre-registration. Investors can also listen to the call through Baxter's website.
Read more →BAXBaxter Publishes 2025 Sustainability Report Highlighting Refreshed Strategy, Ongoing Commitment to Drive Meaningful Impact
Baxter has released its 2025 Sustainability Report, which outlines a refreshed strategy aimed at enhancing its commitment to sustainability. The report emphasizes the company's ongoing efforts to create a meaningful impact in the biopharma sector. Specific details about the initiatives and goals were not disclosed in the article.
Read more →BAXBaxter Reports First-Quarter 2026 Results
Baxter International Inc. reported its first-quarter 2026 results, showing a 3% increase in worldwide sales but a 4% decline in U.S. sales. The company experienced a net loss of $17 million from continuing operations, with adjusted earnings per share down 35% year-over-year. Despite challenges, Baxter is focusing on stabilizing its business and has introduced new products to enhance patient care.
Read more →BAXBAXTER REPORTS FIRST-QUARTER 2026 RESULTS
Baxter International Inc. reported first-quarter 2026 results with sales from continuing operations of $2.7 billion, reflecting a 3% increase on a reported basis but a 1% decline on an organic basis. The U.S. saw a decrease of 4% in sales, contrasting with international sales, which rose 12%. The adjusted diluted earnings per share decreased by 35% from the previous year, prompting the company to reiterate its financial outlook for the year. Overall, the results align with the company's expectations but highlight ongoing challenges in stabilizing certain segments of the business.
Read more →BAXBaxter Showcases Recent Innovations at AORN Global Surgical Conference & Expo 2026
Baxter International Inc. is showcasing innovative surgical solutions at the AORN Global Surgical Conference & Expo 2026. Key highlights include the AAT XR spine surgical table and the Dynamo Series smart stretcher, designed to enhance efficiency and patient safety. These innovations reflect Baxter's commitment to improving care delivery and outcomes in surgical settings.
Read more →BAXBaxter to Host First-Quarter 2026 Financial Results Conference Call for Investors
Baxter International Inc. announced that it will host a conference call to discuss its financial results for the first quarter of 2026. The call is aimed at investors and will provide insights into the company's performance during that period. Further details regarding the timing and access to the call were not provided.
Read more →BAXBaxter Introduces the IV Verify Line Labeling System, an Automated Solution to Improve IV Labeling in Healthcare Settings
Baxter has announced the introduction of the IV Verify Line Labeling System, aimed at enhancing IV labeling processes in healthcare settings. This automated solution is designed to improve accuracy and efficiency in patient care. The initiative reflects Baxter's commitment to innovation in healthcare technology.
Read more →BAXBaxter to Host Annual Meeting of Stockholders in Virtual Format
Baxter International Inc. will conduct its 2026 Annual Meeting of Stockholders virtually on May 5, 2026, starting at 9 a.m. Central Time. Stockholders can access the meeting online and are encouraged to vote their shares in advance. Questions can be submitted before and during the meeting, with answers provided afterward if time constraints prevent live responses.
Read more →BAXExecutive Summary Management and Board of Directors Andrew Hider appointed as President and CEO following a robust search process overseen by a CEO Search Working group consisting of independent directors and conducted w
Baxter International has appointed Andrew Hider as President and CEO, following a thorough search process led by independent directors. This move includes the separation of the CEO and Chair roles to enhance leadership focus. The company has also made significant progress in board refreshment and sustainability initiatives to adapt to changing market dynamics. Overall, the changes are positioned to better align Baxter's leadership with its mission and future goals.
Read more →BAXBAXTER ANNOUNCES CFO TRANSITION
Baxter International Inc. has announced the departure of Chief Financial Officer Joel Grade, who is leaving to focus on family matters but will remain in an advisory role until the end of April 2026. Anita Zielinski has been named as the interim CFO and brings significant experience from her previous roles. The company is committed to maintaining its full-year 2026 financial outlook despite this leadership change. Baxter’s president expressed confidence in the finance team to ensure stability during this transition.
Read more →BAXBaxter Announces CFO Transition
Baxter International Inc. announced the departure of CFO Joel Grade, who will remain in an advisory role until April 30, 2026. Anita Zielinski has been appointed as interim CFO while the company searches for a permanent replacement. Baxter reiterated its financial outlook for 2026, emphasizing its commitment to stability and value creation.
Read more →About Baxter International Inc.
HeadquartersONE BAXTER PARKWAY, DEERFIELD, IL, 60015
Founded1931
BIOPHARMAWATCH ELITE PLUS
Trade the next BAX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime